Health Studies (562 cases, 1,553 controls) and New England Case-Control study (1,821 cases, 1,870 controls). We estimated haplotype scores using expectation-maximizationbased algorithms. We used unconditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CI). We combined study results using DerSimonian and Laird meta-analysis.
INTRODUCTION
Experimental studies suggest that vitamin D and its synthetic derivatives protect against ovarian carcinogenesis, exhibiting antiproliferative, and pro-apoptotic effects in ovarian cancer cell lines (1) (2) (3) (4) and antitumor activity in animal models (5, 6) . The vitamin D receptor (VDR), which binds the biologically active form of vitamin D (1,25- 
dihydroxyvitamin D [1,25(OH)D]), is
weakly to moderately expressed in normal ovarian cells and more strongly expressed in many ovarian cancer cells lines and tumor tissues (2, (7) (8) (9) (10) (11) . Ecological studies generally support the link between vitamin D exposure and ovarian cancer risk, observing higher rates of ovarian cancer incidence and/or mortality among women living in more northern latitudes (12) (13) (14) (15) (16) . However, observational studies using individual-level data on estimated www.frontiersin.org UV radiation exposure, dietary and/or supplemental vitamin D intake, predicted 25(OH)D scores, and plasma 25(OH)D levels have been inconsistent (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) .
Genetic studies may provide another line of evidence for the vitamin D pathway in ovarian carcinogenesis. To date, nine ovarian cancer genetic susceptibility loci have been identified by four genome-wide association studies (GWAS) (31) (32) (33) (34) . While known vitamin D pathway genes do not appear to reside at these loci, the newly established variants explain a relatively small proportion of excess familial risk (34) . Additional common susceptibility loci are likely to exist, but will require alternate approaches such as evaluating gene-environment interaction to discover these associations. Common polymorphisms in the VDR are suspected to either directly affect or be in linkage disequilibrium (LD) with variants that influence vitamin D signaling (35) , which would alter the biological response to vitamin D at the cellular level. Of the VDR variants that have been most extensively studied, the rs228570 T allele [a.k.a. FokI restriction fragment length polymorphism (RFLP) "f " allele] creates a VDR protein that is three amino acids longer and less transcriptionally active than the protein product of the C allele (35) . A recent meta-analysis including a total of 4,163 cases and 6,801 controls observed a significant 9% increase in ovarian cancer risk associated with each rs228570 T allele (36) . While statistically significant associations with ovarian cancer risk were not observed in a meta-analysis for four other VDR variants, total sample sizes were smaller than that for rs228570, thus, reducing power to detect genetic associations (37) . Additionally, vitamin D status of study participants may modify associations between VDR genetic variants and cancer risk (38) (39) (40) (41) , which has not yet been explored for ovarian cancer. Further, risk has not been assessed in relation to GWAS-identified variants linked to lower plasma 25-hydroxyvitamin D [25(OH)D] levels (42) (43) (44) , a relatively stable indicator of vitamin D status (45) .
To explore these gaps, we assessed whether associations between variants presumed to lower VDR bioactivity or contribute to vitamin D insufficiency, and ovarian cancer risk differed by predicted 25(OH)D status in a retrospective case-control study (New England Case-Control study, NECC) and two case-control studies nested within the prospective Nurses' Health Study (NHS) and NHSII cohorts.
MATERIALS AND METHODS

STUDY POPULATIONS
The NHS is a prospective cohort study of 121,700 female registered nurses from 11 US states who were 30-55 years of age in 1976. NHSII began in 1989 and enrolled 116,430 female US registered nurses aged 25-42 from 14 US states. In both cohorts, biennial self-administered questionnaires gathered detailed information on lifestyle, menstrual and reproductive factors, and medical history since baseline. Blood samples were collected from a subset of 32,826 NHS participants in 1989-1990 and from 29,611 NHSII participants from 1996 to 1999. Among women who did not provide a blood sample, buccal cell samples were collected from 29 or 2012 (blood) in NHS with no prior cancer diagnosis except non-melanoma skin cancer. Controls were randomly selected from among women who had at least one ovary and were free of cancer (except non-melanoma skin cancer) up to and including the questionnaire cycle in which the case was diagnosed. Controls were matched to cases by cohort, biospecimen type, age (±1 month), and menopausal status at diagnosis. For participants with blood samples, controls were additionally matched to cases on postmenopausal hormone use (current vs. not current), menopausal status, month/year, time of day, and fasting status at blood collection. Completion of the self-administered questionnaire and submission of the biospecimen was considered to imply informed consent. The NHS and NHSII protocols were approved by the Institutional Review Board of Brigham and Women's Hospital, Boston, MA, USA.
The NECC Study is a population-based study of ovarian cancer. Women residing in eastern Massachusetts or New Hampshire were recruited during three enrollment phases (Phase 1: 1992-1997, Phase 2: 1998 , and Phase 3: 2003 -2008 ), corresponding to three funding periods, the details of which were reported previously (46, 47) . Briefly, 3957 women (1,080 from Phase 1, 1,267 from Phase 2, and 1,610 from Phase 3) residing in eastern Massachusetts or New Hampshire with a diagnosis of incident ovarian cancer were identified from hospital tumor boards and statewide cancer registries. Of the 3,083 eligible women, 2,203 agreed to participate. Controls were identified through a combination of random digit dialing, town books, and drivers' license lists. Exclusion criteria for controls included the inability to be contacted, history of bilateral oophorectomy, language barriers, or relocation outside of the study area. In Phase 1, 420 (72%) of eligible women identified by random digit dialing and 102 (51%) of eligible women identified through town books agreed to participate. In Phase 2 and 3, 4,366 potential controls were identified and 1,578 out of 2,940 eligible women (54%) agreed to participate. Controls were frequency matched to cases by age and study center. At enrollment, participants were asked to recall known and putative ovarian cancer risk factors that occurred ≥1 year prior to diagnosis (for case subjects) or enrollment (control subjects). Over 95% of enrolled participants provided a blood specimen. Each participant provided written informed consent. The Institutional Review Boards of Brigham and Women's Hospital and Dartmouth Medical School, Hanover, NH, USA approved the study protocol.
PREDICTED 25(OH)D SCORES
We used covariate exposures reported closest to the time of blood collection in NHS and NHSII or at enrollment in NECC to calculate menopause-specific predicted 25(OH)D scores as previously described (20, 48) . Briefly, multiple linear regression models to predict 25(OH)D levels within NHS and NHSII were developed and then validated in an independent sample of women with measured 25(OH)D levels (48) . Based on these initial models, separate linear regression models were subsequently fit among 2,431 premenopausal and 3,101 postmenopausal women with measured 25(OH)D levels to create menopause-specific predictor scores (20 (20) . Similarly, we applied these NHS/NHSIIderived beta values as weights for each significant predictor to generate menopause-specific predicted 25(OH)D scores for NECC participants.
SINGLE NUCLEOTIDE POLYMORPHISM SELECTION AND GENOTYPING
We selected commonly studied Single nucleotide polymorphism (SNPs) within the VDR gene that either have known or hypothesized functional effects on VDR activity, expression, and/or cancer risk (35) . Variants putatively associated with reduced VDR activity were designated as the risk alleles. The rs228570 T allele creates a VDR protein that is three amino acids longer and less transcriptionally active than the protein product of the C allele. The G allele of the VDR promoter polymorphism, rs11568820, within the Cdx2 binding site, results in lower binding affinity for the transcription factor. Three SNPs at the 3 end of the VDR: rs1544410, rs7975232, and rs731236 (corresponding RFLPs: BsmI, ApaI, and TaqI) reside in an area of strong LD, and form several haplotypes of which G-C-A (i.e., baT; 48%) and A-A-C (i.e., BAt; 40%) are most common. These haplotypes are in LD with long and short polyA variable number of tandem repeat (VNTR) alleles in the 3 untranslated region (UTR) of the gene, respectively, which may alter VDR mRNA stability or translational activity (35) . We selected another VDR 3 end SNP rs739837 (RFLP BglI) that had been associated with advanced breast cancer risk (50) , and rs1989969 (−5132 T/C), a promoter SNP that eliminates a potential GATA-1 transcription factor binding site (51) . Additionally, we genotyped GWAS-identified SNPs at loci associated with plasma 25(OH)D levels [cytochrome P450, family 2, subfamily R, polypeptide 1 (CYP2R1; rs10741657 and rs2060793); NAD synthase 1 (NADSYN1)/7-dehydrocholesterol reductase (DHCR7 ; rs1790349 and rs3829251); group-specific component (GC; rs2282679, rs4588, and rs7041), which is also commonly known as vitamin D binding protein (VDBP); cytochrome P450, family 24, subfamily A, polypeptide 1 (CYP24A1; rs6013897)] (42) (43) (44) . Three of the GWAS loci also were significantly associated with clinical vitamin D insufficiency (<75 nmol/L) (42) . Variants associated with lower plasma 25(OH)D were considered risk alleles.
Existing genotype data on rs11568820, rs1544410, rs2282679, rs228570, and rs7041 were available for NECC Phase 1 and 2 participants from previous analyses (34, 52) , whereas genotype data for NHS, NHSII, and NECC Phase 3 participants were newly generated for this project. All 15 VDR and vitamin D insufficiency GWAS SNPs were genotyped in NHS and NHSII samples. To increase sample size for haplotype analyses, we additionally genotyped rs1544410, rs4588, rs7041, rs731236, and rs7975232 in NECC Phase 3 samples. Sample sizes for each SNP analyzed are reported in Table S1 in Supplementary Material. Genomic DNA was extracted from buffy coat or buccal cell samples using the QIAamp (Qiagen, Chatsworth, CA, USA) 96-spin blood protocol. DNA from NHS and NHSII participants was whole genome amplified with GE Healthcare Genomiphi (GE Healthcare BioSciences Corp., Piscataway, NJ, USA). Genotyping was performed at the Dana Farber/Harvard Cancer Center High-Throughput Genotyping Core using the 5 nuclease assay (Taqman, Applied Biosystems, Foster City, CA, USA) on the OpenArray® RealTime PCR System (Applied Biosystems; NHS/NHSII samples) on amplified DNA or the ABI PRISM® 7900HT Sequence Detection System on genomic DNA (NECC Phase 3 samples). Laboratory personnel were blinded to case-control status, and each plate included replicate samples for quality control, which had 100% concordance.
25-HYDROXYVITAMIN D PLASMA ASSAY
Existing plasma 25(OH)D levels were available for a subset of NHS and NHSII participants (N = 570), as described previously (52, 53) . Briefly, case-control sets and samples from the same cohort were assayed together by radioimmunoassay and labeled to mask case-control status. The intra-assay coefficients of variation, based on blinded quality control replicates ranged from 8 to 10%.
STATISTICAL ANALYSIS
We used chi-square tests to assess Hardy-Weinberg equilibrium (HWE) among white controls within NHS/NHSII and NECC. Three of 15 SNPs (rs1989969, rs2060793, and rs739837) were out of HWE among NHS/NHSII participants (P < 0.05) and excluded from analyses. We excluded NHS/NHSII samples that failed genotyping of five or more SNPs (15 cases, 41 controls). Among NECC participants, rs1544410 was out of HWE (P = 0.004). Review of screen shots for these plates revealed appropriate clustering and so rs1544410 was retained to generate VDR 3 end haplotypes. The rs1544410 risk allele frequency (RAF) among NECC controls was similar to the RAF among NHS/NHSII controls and the HapMap Phase II + III, Release 28 Caucasian European (CEU) population (Table S1 in Supplementary Material).
We used unconditional logistic regression models adjusted for matching factors and race to calculate odds ratios (ORs) and 95% confidence intervals (CIs). For each SNP, gene dosage effects were modeled by assigning a value of 0, 1, or 2 to a genotype trend variable according to a participant's number of risk alleles. We estimated frequencies of VDR 3 end and GC haplotypes using expectation-maximization-based algorithms and imputed subject-specific expected haplotypes (54, 55) to provide tests of association for individual haplotypes, assuming additive inheritance models. VDR 3 end haplotypes with estimated frequencies <5% were grouped. We derived estimated GC phenotypes based on GC haplotype scores and assigned www.frontiersin.org were performed by the Wald test using cross-product terms. DerSimonian and Laird random effects meta-analysis (57) was used to combine results from NHS/NHSII and NECC. Heterogeneity by study and by predicted 25(OH)D strata was calculated using the Q statistic. To calculate a global P value for statistical interaction of VDR 3 end haplotypes by predicted 25(OH)D status, we pooled individual-level NHS/NHSII and NECC data, additionally adjusted for study and predicted 25(OH)D scores, and compared models with interaction terms to a model without interaction terms using the likelihood ratio test.
P values were based on two-sided tests and considered statistically significant at P < 0.05. All analyses were conducted using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). Power calculations were performed using QUANTO (58) .
RESULTS
A total of 2,383 (562 NHS/NHSII and 1,821 NECC) cases and 3,423 (1,553 NHS/NHSII and 1,870 NECC) controls were available for this analysis. Women ranged in age from 34 to 72 years in NHS/NHSII and from 18 to 79 years in NECC at the time of blood collection. As expected based on the matched designs, cases, and controls were of similar age within each study. On average, NHS/NHSII participants were slightly older than NECC participants at the time of blood collection. Within each study, cases had shorter mean duration of oral contraceptive use and were less likely to have had a tubal ligation than controls. BMI, total leisure-time physical activity, total vitamin D intake (food and supplemental sources), and alcohol consumption were similar between case and control groups. Total vitamin D intake was higher in NECC than in NHS/NHSII ( Table 1) .
Risk allele frequencies observed in our control groups were comparable to those in the CEU HapMap population (Table  S1 in Supplementary Material). Genotyping success rates were ≥95% for all SNPs except rs7975232 in NHS/NHSII (93%) and rs2228570 in NECC (94%). Given high LD between rs1790349 and rs3829251 (r 2 = 0.79) at the NADSYN1/DHCR7 locus and between rs2282679 and rs4588 (r 2 = 0.95) at the GC locus among NHS/NHSII participants, we selected the SNP with the higher genotyping success rate for analysis (rs3829251 and rs4588). We did not observe significant heterogeneity in estimates between NHS/NHSII and NECC in the main effect metaanalysis of SNPs. Of the VDR SNPs assessed, we observed a significant 12% increased risk of ovarian cancer associated with each rs7975232 A allele ( Table 2) . A marginal association between rs2228570 and ovarian cancer risk was also observed (per T allele OR = 1.09, 95% CI = 1.00-1.19; P trend = 0.06). The GWAS-identified rs7041 T allele was significantly associated with reduced ovarian cancer risk (per allele OR = 0.92, 95% CI = 0.85-0.99; P trend = 0.03). We confirmed that the rs7041 T allele and the vitamin D insufficiency GRS were associated with reduced 25(OH)D levels (P trend of 0.005 and <0.0001, respectively) among the subset of NHS/NHSII participants with existing 25(OH)D measurements (N = 570). The vitamin D insufficiency GRS was not associated with ovarian cancer risk (data not shown).
We took advantage of the strong LD at the 3 end of the VDR gene (35) to generate haplotype scores that may better capture the effect of an unknown functional variant. Three SNPs at the VDR 3 end (rs1544410-rs7975232-rs731236) formed three common haplotypes and five haplotypes with frequencies <5% that were grouped into a "rare" haplotype variable. Ovarian cancer risk was not associated with the VDR 3 end haplotypes compared 
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.88) in a subset of New England Case-Control study participants (950 cases and 1,052 controls) that were genotyped on the iCOGS array (34).
to the most common haplotype (G-C-T) in the meta-analysis of NHS/NHSII and NECC ( Table 3) .
GC SNPs rs7041 and rs4588 create amino acid substitutions at positions 416 and 420, respectively, resulting in three major VDBP isoforms (GC2, GC1s, and GC1f) that vary in binding affinity for vitamin D analytes (56) . We confirmed that allelic combinations ("GC phenotypes"; see Table 3 footnote) estimated to have higher VDBP binding affinity were positively associated with plasma 25(OH)D levels in NHS/NHSII (P trend = 0.003). Estimated GC phenotypes were not associated with ovarian cancer risk in NHS/NHSII, NECC, or the meta-analysis (P trend ≥ 0.31; Table 3 ).
Evidence of effect modification by vitamin D exposure has been observed in prior studies of other cancers. Stronger genetic associations with prostate cancer risk were observed for VDR variants among men with vitamin D insufficiency or low sun exposure (38) (39) (40) . In contrast, the BsmI B allele was somewhat more strongly associated with melanoma risk among participants with higher sun exposure (41) . Therefore, we explored the relation between ovarian cancer and individual SNPs, VDR 3 end haplotypes, and estimated GC phenotypes by predicted 25(OH)D strata. Among women with high (above the median) predicted 25(OH)D levels, we observed significant increased risk of ovarian cancer associated with VDR variants rs731236 (per allele C OR = 1.31, 95% CI = 1.11-1.55; P trend = 0.002) and rs7975232 (per A allele OR = 1.38, 95% CI = 1.17-1.62; P trend = 0.0002; Table 4 ). These SNPs were not associated with ovarian cancer risk among women with low predicted 25(OH)D levels (P heterogeneity of 0.009 and 0.006, respectively). Similarly, heterogeneity in ovarian cancer risk by predicted 25(OH)D was observed for the VDR 3 end haplotypes (P = 0.009; Table 5 ). For each A-A-C or G-A-T haplotype possessed by women with high predicted 25(OH)D levels, risk of ovarian cancer significantly increased~40%. These associations were not observed among women with low predicted 25(OH)D. To determine whether a particular component of the predicted 25(OH)D score accounted for the heterogeneity, we tested effect modification of ovarian cancer associations with rs731236, rs7975232, and VDR 3 end haplotypes by BMI (<25 vs. 25+ kg/m 2 ), total vitamin D intake (below vs. above median), total leisure-time physical activity (below vs. above median), menopausal status and HT use (premenopausal, postmenopausal/never HT use, postmenopausal/past HT use, and postmenopausal/current HT use), and alcohol intake (below vs. above median). Except for heterogeneity in the rs731236 association with ovarian cancer risk by alcohol intake (P = 0.03), in which the increased risk was restricted to women with higher than the median alcohol intake, we did not observe significant effect modification by predicted 25(OH)D score components (data not shown). The GC rs7041 T allele was associated with reduced ovarian cancer risk among women with low predicted 25(OH)D (P trend = 0.03), but the association was not significantly different from that of women with high predicted 25(OH)D (P heterogeneity = 0.39; Table 4 ). Estimated GC phenotypes were not associated with ovarian cancer risk regardless of predicted 25(OH)D status ( Table 5) .
DISCUSSION
In this study, we examined whether the vitamin D status of individuals modifies genetic associations between VDR variants and www.frontiersin.org GC1s-GC1f, 8.6; 11.2 (56) .
ovarian cancer risk. Our results provide some evidence that genetic variation at the 3 end of the VDR gene (rs731236, rs7975232, 3 end haplotypes) may influence ovarian cancer risk among women with higher predicted 25(OH)D levels, but not among women with lower levels. This also is the first report to assess whether vitamin D insufficiency GWAS loci are associated with risk. Based on the anti-proliferative and pro-apoptotic effects of vitamin D on ovarian cancer cell lines (1-4) , the rs7041 vitamin D insufficiency risk (T) allele was unexpectedly associated with reduced risk of ovarian cancer in our datasets. Outside of the VDR 3 end genetic variants, we did not observe effect modification by predicted 25(OH)D status for the other examined variants. Overall, we observed that some, but not all, genetic variation at the 3 end of the VDR gene is associated with a modestly increased risk of ovarian cancer. Known vitamin D pathway genes do not appear to reside at the nine susceptibility loci newly identified by ovarian cancer GWAS studies conducted among women from North America and the UK (31) (32) (33) (34) . In a US GWAS of ovarian cancer (n = 1,814 cases and 1,867 controls from four studies), there was no association between the 3 end haplotypes and ovarian cancer risk (unpublished data). However, in our study, we only observed a positive association for individuals with higher predicted 25(OH)D status. Since a substantial portion of the US and UK populations have insufficient vitamin D levels (59, 60) , it may be difficult to observe genetic associations without considering the vitamin D status of women. The biologic implications of our results are not entirely clear as we observed heterogeneity by predicted 25(OH)D status for variants with unknown functional significance. VDR 3 end haplotypes are in strong LD with regulatory elements in the 3 UTR, which may alter VDR mRNA stability or translational activity. However, reported directions of association between 3 end haplotypes and VDR expression and/or activity have been inconsistent, which may be due to tissue-specific regulation (35) . Alternatively, the VDR 3 variants could be in LD with variants influencing activity and/or expression of neighboring genes such as histone deacetylase 7 (HDAC7 ), which begins 21.6 kb downstream of the VDR gene. HDAC7 has been shown to attenuate 1,25(OH)D-mediated gene transcription in malignant breast cells (61) . Investigating the influence of VDR 3 end variants on expression and/or activity of the VDR and neighboring genes in ovarian cells as well as potential vitamin D activation of the receptor may provide insight on the relation with ovarian cancer risk.
An experimental study demonstrated that 1,25(OH)Dstimulated VDR activity differed by naturally occurring rs2228570 genotype in peripheral blood mononuclear cells in vitro (62) . The T allele exhibited a dose-dependent effect on the halfmaximal activity of 1,25(OH)D, in which higher concentrations were required to obtain similar inhibition of cell proliferation. However, the polymorphism was not associated with maximal 1,25(OH)D-mediated growth inhibition. 1,25(OH)D half-maximal and maximal growth inhibition did not differ by rs1544410, rs731236, rs7975232 genotypes, or VDR 3 end haplotypes (62) . The authors noted that the lack of heterogeneity by VDR 3 end haplotypes potentially could have been due to small sample size (62), which may be true for the individual variants as well. Likewise, as common variants often exhibit weak effects on associated phenotypes, our analysis was not sufficiently powered to detect small differences in ovarian cancer risk by genotype, which may have contributed to inconsistency between our study and the experimental study. For example, based on our observed estimates within predicted 25(OH)D strata, our power to detect significant relative ORs of~1.06 for rs2228570 and~1.15 for rs1544410 were 10 and 43%, respectively. Further, while the predicted 25(OH)D score is significantly positively correlated with plasma 25(OH)D levels (48), we cannot estimate absolute levels to determine which subgroup of women are exposed to half-maximal concentrations of 25 We hypothesized that validated GWAS variants associated with lower plasma 25(OH)D levels would result in a lower lifetime average plasma 25(OH)D levels, increasing risk of ovarian cancer. Individual vitamin D insufficiency variants and the GRS were associated with plasma 25(OH)D in the expected direction among the subgroup of NHS/NHSII women with measured levels, but were not associated with ovarian cancer risk. Contrary to expectations, the rs7041 T allele was associated with reduced ovarian cancer risk (P = 0.03). The association could be due to chance considering the number of statistical tests performed in this study. Another possibility is that because rs7041, in combination with rs4588, forms three major VDBP isoforms (GC2, GC1s, and GC1f), and the rs7041 T allele codes for isoforms with both the lowest (GC2) and highest (GC1f) binding affinity (56) , our study population may have a higher prevalence of the GC1f compared to the GC2 isoform. However, consistent with prior reports of race-specific frequencies (63) , the frequency of GC2 (~0.28) was higher than that of GC1f (~0.15) among our predominantly white study populations. The trend variable of estimated GC phenotypes ordered by increasing binding affinity was associated with higher plasma 25(OH)D, but not ovarian cancer risk in our study. Stratifying by predicted 25(OH)D did not identify ovarian cancer associations with individual GWAS variants nor with estimated GC phenotypes. While we adjusted our analyses for self-reported race, given racial differences in VDBP isoform frequencies (63) , and in risk of ovarian cancer (64), we cannot exclude the possibility that underlying population stratification may have confounded our results. Estimates for all of our analyses were similar when we excluded women of self-reported non-European ancestry (NHS/NHSII: 29 cases, 74 controls; NECC: 89 cases, 57 controls).
Our study has several strengths and limitations. While our study benefited from a relatively large sample size for the main effects on at least a subset of examined SNPs, power to detect heterogeneity by predicted 25(OH)D status was generally limited. Moreover, the numerous hypotheses tested relating to SNP main effects, haplotypes, predicted 25(OH)D strata, and interactions increased the likelihood of observing false positive results. Even so, increased ovarian cancer risk associated with rs7975232 and the A-A-C 3 end haplotype at the VDR locus among women with higher predicted 25(OH)D scores remained significant after adjusting the significance level using a Bonferroni correction (0.05/54 = 0.0009). The risk associated with VDR variant rs731236 among this same subgroup of women also remained significant using the less conservative False Discovery Rate procedure (65) . Our analyses were aided by the predominantly white study populations, but lacked ancestry informative markers to control for potential population stratification. Further, our results may not be generalizable to nonwhite populations, particularly for VDBP isoforms, the frequencies of which are known to vary substantially by race (63) . Use of the questionnaire-based predicted 25(OH)D score made our large study feasible. In general, the heterogeneity observed by predicted 25(OH)D status did not appear to be driven by a single component of the score predicting 25(OH)D, but rather by the score in its entirety. However, we are unable to directly translate the predicted 25(OH)D score into absolute 25(OH)D levels. Future follow-up studies with measured plasma 25(OH)D levels on a larger study www.frontiersin.org 
